Pharming Group (PHGUF) Stock Forecast, Price & News

Pharming Group (OTCMKTS:PHGUF) Frequently Asked Questions

Is Pharming Group a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharming Group in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Pharming Group stock.
View analyst ratings for Pharming Group or view top-rated stocks.

Are investors shorting Pharming Group?

Pharming Group saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 1,525,800 shares, an increase of 31.7% from the April 15th total of 1,158,400 shares. Based on an average trading volume of 400 shares, the days-to-cover ratio is currently 3,814.5 days.
View Pharming Group's Short Interest.

How were Pharming Group's earnings last quarter?

Pharming Group (OTCMKTS:PHGUF) issued its earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a trailing twelve-month return on equity of 8.30% and a net margin of 8.04%.
View Pharming Group's earnings history.

What price target have analysts set for PHGUF?

1 analysts have issued 1 year price objectives for Pharming Group's stock. Their forecasts range from $3.10 to $3.10. On average, they anticipate Pharming Group's share price to reach $3.10 in the next twelve months. This suggests a possible upside of 266.9% from the stock's current price.
View analysts' price targets for Pharming Group or view top-rated stocks among Wall Street analysts.

Who are Pharming Group's key executives?

Pharming Group's management team includes the following people:

• Dr. Sijmen de Vries M.B.A., M.D., MBA, Pres, CEO & Exec. Director (Age 63, Pay $1.1M)
• Dr. Bruno M. L. Giannetti, Consultant (Age 70, Pay $659.18k)
• Mr. Jeroen Wakkerman, Chief Financial Officer (Age 53)
• Ms. Mireille Sanders M.Sc., Chief Operations Officer (Age 54)
• Dr. Robert Friesen Ph.D., Chief Scientific Officer (Age 58)
• Susanne Embleton, Investor Relations Mang.
• Mr. Ruud Van Outersterp, Chief Ethics & Compliance Officer (Age 58)
• Mr. Anurag Relan, Chief Medical Officer (Age 50)
• Mr. Paul Th. Jansse, VP & Head of Non-US Commercial Operations (Age 53)
• Mr. Stephen Toor, Chief Commercial Officer & GM of Americas (Age 51)

Who are some of Pharming Group's key competitors?

Some companies that are related to Pharming Group include Lonza Group (LZAGY), Imperial Brands (IMBBY), Turning Point Brands (TPB), Healthier Choices Management (HCMC) and Gilla (GLLA).
View all of PHGUF's competitors.

What is Pharming Group's stock symbol?

Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF."

How do I buy shares of Pharming Group?

Shares of PHGUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharming Group's stock price today?

One share of PHGUF stock can currently be purchased for approximately $0.85.

How much money does Pharming Group make?

Pharming Group has a market capitalization of $528.87 million and generates $198.87 million in revenue each year. The biotechnology company earns $16 million in net income (profit) each year or $0.019990 on an earnings per share basis.

How many employees does Pharming Group have?

Pharming Group employs 277 workers across the globe.

What is Pharming Group's official website?

The official website for Pharming Group is www.pharming.com.

How can I contact Pharming Group?

Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The biotechnology company can be reached via phone at (171) 524-7400, via email at [email protected], or via fax at 31-0-71-524-7445.